Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 12/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.46 |
| ▸ | F2R | P25116 | 1/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.42 |
| ▸ | FAP | Q12884 | 1/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | PADI1 | Q9ULC6 | 1/20 | 0.40 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | REN | P00797 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30800861 | 0.87 | DPP4 (0.43) | DPP4DPP8FAPDPP9DPP7 | |
| SCHEMBL30169755 | 0.85 | ACE (0.47) | DPP4DPP8FAPDPP9DPP7 | |
| SCHEMBL30906704 | 0.83 | DPP4 (0.46) | DPP4DPP8FAPDPP9DPP7 | |
| SCHEMBL29397117 | 0.81 | DPP4 (0.46) | DPP4ITGB1ITGA4DPP8FAP | |
| SCHEMBL30051232 | 0.81 | KMT2A (0.51) | DPP4DPP8FAPDPP9DPP7 | |
| SCHEMBL29438447 | 0.81 | DPP4 (0.43) | DPP4ITGB1ITGA4DPP8FAP | |
| SCHEMBL29408003 | 0.80 | DPP4 (0.45) | DPP4DPP8FAPDPP9DPP7 | |
| SCHEMBL30972553 | 0.80 | KMT2A (0.42) | DPP4ITGB1ITGA4DPP8FAP | |
| SCHEMBL29397226 | 0.79 | DPP4 (0.44) | DPP4ITGB1ITGA4DPP8FAP | |
| SCHEMBL30800860 | 0.79 | DPP4 (0.44) | DPP4DPP8FAPDPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3688007-B1 | BIOCONJUGATION OF POLYPEPTIDES | UNIV YORK (GB) | 2024-07-31 | — | — | EP | disclosed |
| US-11897917-B2 | Bioconjugation of polypeptides | THE UNIVERSITY OF YORK (GB) | 2024-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11897917-B2 | Bioconjugation of polypeptides | PTMS, EPCAM, IAPP | DPP4 1509/4885ITGB3 918/4885ITGA2B 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.